Explore the Agenda

8:00 am Check-In & Coffee

8:50 am Chair’s Opening Remarks

Driving Quality Through Drug Substance & Raw Material Characterization

9:00 am The Application of Trans-Amplifying RNA in Targeted & Untargeted LNP Systems

Senior Scientist,, Amplitude Therapeutics
  • Characterize the unique analytical requirements of trans-amplifying RNA systems, including multi component payload composition, RNA integrity, and encapsulation performance
  • Compare targeted and untargeted LNP approaches to understand how delivery strategy influences cargo behavior and analytical requirements
  • Develop analytical frameworks that connect cargo quality to potency, comparability, and translational readiness

9:30 am Session Details to Be Released

Right click on the image to save it to your computer.

10:00 am Multi-Attribute Methods for RNA-LNP Characterization: Promise, Pitfalls & GMP Readiness

Principal Scientist, Genomic Medicine Unit Analytical Development,, Sanofi
  • Learn how multi-attribute methods can consolidate multiple assays into a single analytical workflow, reducing testing burden while increasing product understanding
  • Evaluate the challenges of method robustness, reliability, and validation when transitioning complex methods into GMP environments
  • Determine when multi-attribute approaches are appropriate and how to balance efficiency with risk in release and control strategies

10:30 am Morning Break & Networking

11:30 am Strengthen Targeted LNP Performance Through Advanced Characterization Strategies

Director, Nava Therapeutics
  • Develop quantitative and qualitative assays to accurately characterize targeted LNP composition and surface modifications
  • Assess protein quality, conjugation efficiency, and surface integrity to ensure consistent targeting performance
  • Link analytical characterization to biological function to support robust development, comparability, and translational success

12:00 pm Session Details to Be Released

Right click on the image to save it to your computer.

12:10 pm Systematic Evaluation of RiboGreen-Based Encapsulation Efficiency Measurements for Lipid Nanoparticles

Analytical Advisor, Eli Lilly & Co.
  • Evaluate total and free RNA assays to identify root causes of variability in EE% measurement
  • Identify that nanoparticle-mediated fluorescence attenuation results in free assay imprecision
  • Demonstrate that matrix-matched calibration restores EE% accuracy in both LNP and targeted LNP

12:40 pm Lunch Break & Networking

Next-Generation Multi-Cargo & Complex LNP Systems

1:40 pm Characterizing Targeted LNPs for In Vivo T Cell & Hematopoietic Stem Cell Delivery: Analytical Insights from Discovery Through Translation

Principal Scientist,, Tessera Therapeutics
  • Identify the analytical attributes that influence targeting efficiency and in vivo performance of tLNP systems
  • Explore characterization strategies to assess surface properties, composition, heterogeneity, and structure–function relationships across CAR-T and SCD programs
  • Demonstrate how analytical insights support scale-up, comparability, and translational readiness from discovery through development

2:10 pm Roundtable: What’s Holding Back In Vivo CAR-T? Tackling the Biggest Analytical Bottlenecks

Senior Associate Scientist,, Stylus Medicine
Senior Scientist,, Prime Medicine

Collaborative problem-solving session where participants from companies developing in vivo CAR-T therapies share challenges and brainstorm solutions for T-cell targeting, biodistribution assessment, and potency measurement

  • Discuss the toughest characterization challenges facing in vivo CAR-T developers today
  • Benchmark analytical strategies for targeted delivery, potency, and product understanding
  • Generate practical solutions through facilitated peer discussion and shared experiences

3:00 pm Afternoon Break & Networking

4:00 pm Characterize Gene Editing LNPs with Multiple Payloads of Different Sizes

Senior Scientist,, Prime Medicine
  • Measure co-encapsulation efficiency of mRNA and guide RNA, quantify payload ratios, ensure consistent product composition
  • Assess stability of multi-component systems, identify degradation pathways for each cargo, develop orthogonal methods
  • Correlate analytical profiles to editing efficiency, optimize formulations based on data, accelerate development timelines

4:30 pm Overcoming Barriers to T-Cell Delivery with Next-Generation LNPs

Senior Director, Head of Non-Viral Delivery,, Granza Bio
  • Understand the key challenges limiting T-cell targeting and in vivo delivery
  • Explore emerging LNP designs and targeting strategies for improving delivery efficiency
  • Learn how next-generation delivery platforms are enabling new gene editing and immunotherapy applications

5:00 pm Chair’s Closing Remarks

5:15 pm End of Conference Day Two